Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 3/20 | 0.36 |
| ▸ | AKT2 | P31751 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.35 |
| ▸ | PDE4A | P27815 | 4/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 1/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10248934 | 0.90 | PDE1A (0.39) | MAPTPOLBSMN1; SMN2AKT1AKT2 | |
| SCHEMBL10249030 | 0.89 | POLB (0.40) | POLBSMN1; SMN2AKT1AKT2PDE10A | |
| SCHEMBL10249089 | 0.87 | POLB (0.40) | POLBSMN1; SMN2AKT1AKT2PDE10A | |
| SCHEMBL117769 | 0.87 | POLB (0.42) | MAPTPOLBSMN1; SMN2PDE10APDE4A | |
| SCHEMBL10249141 | 0.87 | POLB (0.37) | MAPTPOLBSMN1; SMN2AKT1AKT2 | |
| SCHEMBL10248946 | 0.87 | SMN1; SMN2 (0.37) | POLBSMN1; SMN2AKT1AKT2PDE10A | |
| SCHEMBL10249232 | 0.86 | BUB1 (0.39) | MAPTPOLBSMN1; SMN2AKT1AKT2 | |
| SCHEMBL10249083 | 0.84 | POLB (0.50) | POLBSMN1; SMN2AKT1AKT2PDE10A | |
| SCHEMBL10249154 | 0.84 | POLB (0.38) | POLBSMN1; SMN2AKT1AKT2PDE10A | |
| SCHEMBL10249052 | 0.84 | MAPT (0.46) | MAPTPOLBSMN1; SMN2PDE10APDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461181-B2 | Fused heterocyclic compound and use thereof | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8273764-B2 | Fused heterocyclic compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120178779-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-07-12 | — | — | US | disclosed |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178779-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | C3AR1, C9, C5 | MAPT 4423/4885POLB 4724/4885SMN1; SMN2 1524/4885 |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | C3AR1, C9, C5 | MAPT 4423/4885POLB 4724/4885SMN1; SMN2 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.